In pursuit of our mission, the Center conducts research on medical, behavioral, and combination approaches to the prevention and treatment of chronic illnesses, with a particular focus on addiction and HIV. We also host a data safety and monitoring board that provides support and oversight to dozens of researchers. We stress the values of integrity and scientific rigor in the conduct of our research and work closely with the communities we serve to ensure that the best of care is given.

 

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

DESCRIPTION: The primary objective of this double-blind, placebo-controlled, adaptive, randomized clinical trial is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary outcomes will assess the safety of naltrexone plus bupropion and determine the efficacy of the combination pharmacotherapy on other substance use outcomes, on depression symptom scores, and on quality of life ratings. 370 individuals with moderate or severe methamphetamine use disorder will be randomly…

Read More

Combating Craving with Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa

RELEVANCE: Methamphetamine (MA) addiction is a global health problem with high prevalence and great social and health costs in the United States and in the Republic of South Africa and there is a strong need for development and implementation of effective MA treatment approaches. DESCRIPTION: This study will enroll treatment-seeking, MA-dependent individuals into an 8-week contingency management (CM) program. At the beginning and end of the program, participants will participate in MRI scans while performing…

Read More

HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis (PrEP) in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

RELEVANCE: PrEP agents are needed that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen. DESCRIPTION: Once randomized to one of two arms, participants will move through the steps below and followed for up to…

Read More

HPTN 085: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection (AMP)

RELEVANCE: Preliminary data have shown antibodies to be a potential efficacious intervention in preventing HIV-1 infection. DESCRIPTION: This study will evaluate the safety, tolerability, and efficacy of the VRC01 antibody in preventing HIV-1 infection in healthy adults at high risk of HIV infection. Participants will be men who have sex with men (MSM) and transgender people in the U.S., Peru and Brazil. An equal number of study participants will be randomized to receive VRC01 mAb…

Read More

MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE), better known as the M Study

RELEVANCE: Stimulant use, especially among men who have sex with men (MSM) in Los Angeles County (LAC) is common.  Stimulant drug use, particularly methamphetamine use, is a significant factor in the progression of HIV and STI among MSM in LAC.  Non-white MSM are at greatest risk of HIV infection in the United States.  Analyses of drug use are needed among diverse samples of MSM in order to understand the impact of drug use on the…

Read More

Phase 1 Safety-Interaction Study of Pomaglumetad Methionil For Methamphetamine Use Disorder

RELEVANCE: Despite multiple clinical trials testing medications targeting dopaminergic, serotonergic, cholinergic, and gaba-ergic systems, no effective medication for methamphetamine (MA) use disorder is currently available. DESCRIPTION: This is an inpatient, phase I safety-interaction trial of POMA (Pomaglumetad Methionil) in participants with MA (methamphetamine) use disorder. The goal of the study is to provide the initial safety, tolerability, and pharmacokinetic (PK) data required by the FDA to advance POMA to phase 2 safety and efficacy testing.…

Read More

Phase II Randomized Trial of Ibudilast For Methamphetamine Dependence

RELEVANCE: Despite numerous clinical trials, no medication has been approved to treat methamphetamine (MA) dependence. As a result, novel approaches to medication development for MA dependence, including linked medication development, where work in early safety trials can be used to inform the importance of continued (or not) assessment of novel or combination pharmacotherapies, is needed. DESCRIPTION: Following up on the Phase I safety trial, the objective of this study is to test the safety and…

Read More

The LA PrEP Stories Project

RELEVANCE: Pre-Exposure Prophylaxis (PrEP) has the potential to reduce the number of new HIV infections among high-risk black and Latino men who have sex with men (BLMSM). However, issues related to the adoption of PrEP may negatively influence PrEP disclosure, diffusion, adherence and retention among BLMSM who adopt PrEP. The findings from this study will inform the development of intervention activities that seeks to prevent or moderate the negative social experiences associated with PrEP adoption…

Read More

FREE CONDOMS

According to a 1992 study published in the Journal of Sexually Transmitted Diseases, using a condom makes sex 10,000 times safer than not using a condom. The UCLA Vine Street Clinic has partnered with LA County to provide free condoms to the public. For more information, visit http://lacondom.com/find-free-condoms/

Read More